ストックスクリーナーアプリを入手
8.22
2.95%
-0.25
アフターアワーズ：
8.65
0.43
+5.23%
Omeros Corporation (OMER) 最新ニュース
Earnings call transcript: Omeros Q4 2024 sees narrower EPS loss, stock climbs - Investing.com India
Omeros: Q4 Earnings Snapshot - MySA
Omeros beats Q4 earnings estimates, shares rise 5% - Investing.com
OMEROS CORP SEC 10-K Report - TradingView
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results - Yahoo Finance
Omeros (OMER) to Release Quarterly Earnings on Monday - Defense World
Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings - Benzinga
In the Green: Omeros Corporation (OMER) Closes at 8.52, Up/Down -6.99 from Previous Day - DWinneX
Omeros Corporation (OMER) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Trend Tracker for (OMER) - news.stocktradersdaily.com
Strong Buy Rating for Omeros Corporation Driven by Promising Narsoplimab Prospects and Strategic Advancements - TipRanks
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025 - Joplin Globe
Charles Schwab Investment Management Inc. Decreases Stock Holdings in Omeros Co. (NASDAQ:OMER) - Defense World
Bank of New York Mellon Corp Sells 4,919 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Omeros to activate site for Phase III programme of zaltenibart for PNH - Yahoo Finance
Omeros Co. (NASDAQ:OMER) Shares Sold by Bank of New York Mellon Corp - The AM Reporter
D. Boral Capital Reaffirms Buy Rating for Omeros (NASDAQ:OMER) - Defense World
Omeros (OMER) Expected to Announce Earnings on Monday - Defense World
Omeros advances Phase 3 trials for PNH treatment zaltenibart - Investing.com
Omeros Says Trial Site Activation Underway for Phase 3 Study of Zaltenibart -March 21, 2025 at 12:53 pm EDT - MarketScreener
Omeros advances Phase 3 trials for PNH treatment zaltenibart By Investing.com - Investing.com South Africa
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program - The Joplin Globe
Omeros (NASDAQ:OMER) Downgraded by StockNews.com to Sell - Defense World
US Bancorp DE Takes $81,000 Position in Omeros Co. (NASDAQ:OMER) - Defense World
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
(OMER) On The My Stocks Page - Stock Traders Daily
Omeros Corporation Receives Commitment Of Over $4 Million From Nida For Further Development Of The Company'S Oms527 Program To Treat Cocaine Use Disorder - Marketscreener.com
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder - Yahoo Finance
Major Breakthrough: First-Ever Cocaine Addiction Drug Receives $4M NIDA Funding - Stock Titan
Omeros (NASDAQ:OMER) Stock Rating Upgraded by StockNews.com - Defense World
Omeros Co. (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Omeros (NASDAQ:OMER) Rating Lowered to Sell at StockNews.com - Defense World
New York State Common Retirement Fund Increases Stake in Omeros Co. (NASDAQ:OMER) - Defense World
The time has not yet come to remove your chips from the table: Omeros Corporation (OMER) - SETE News
Investor Network: Omeros Corporation to Host Earnings Call - ACCESS Newswire
Blue Trust Inc. Sells 1,910 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Loss-Making Omeros Corporation (NASDAQ:OMER) Expected To Breakeven In The Medium-Term - Simply Wall St
Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us (OMER) - Seeking Alpha
Trading (OMER) With Integrated Risk Controls - Stock Traders Daily
Omeros Corporation Announces Statistical Analysis Results for Expanded Access ProgramSeattle, Washington–(BUSINESS WIRE)–Feb 20, 2025–Omeros Corporation (NASDAQ: OMER) announced today the statistical analysis results related to the expande - Defense World
Omeros announces results for narsoplimab expanded access program - Yahoo Finance
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA - Business Wire
Can This Drug Cut Death Risk by 66% in Transplant Patients? New Data Reveals Breakthrough - Stock Titan
Brokerages Set Omeros Co. (NASDAQ:OMER) Price Target at $22.50 - MarketBeat
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings - Business Wire
Breakthrough TA-TMA Treatment Data: Narsoplimab Shows Promising Results in 128-Patient Study - StockTitan
Omeros Co. (NASDAQ:OMER) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program - BioSpace
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes Of Narsoplimab Treatment For Ta-Tma - Marketscreener.com
Institutions own 43% of Omeros Corporation (NASDAQ:OMER) shares but retail investors control 53% of the company - Yahoo Finance
SG Americas Securities LLC Has $241,000 Position in Omeros Co. (NASDAQ:OMER) - Defense World
Navigating OMER Stock: Omeros Corporation Journey - The InvestChronicle
Stordahl Capital Management Inc. Purchases New Shares in Omeros Co. (NASDAQ:OMER) - MarketBeat
Omeros (NASDAQ:OMER) Trading Up 5.3%Here's What Happened - MarketBeat
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):